Jennison Associates
BPMC

Jennison Associates’s Blueprint Medicines BPMC Stock Holding History

Jennison Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-348,817
Closed -$30.9M – 587
2025
Q1 		$30.9M Sell
348,817
-11,391
-3% -$1.11M 0.02% 270
2024
Q4 		$31.4M Buy
+360,208
New +$33M 0.02% 292
2022
Q1 		– Sell
-251,237
Closed -$26.9M – 638
2021
Q4 		$26.9M Sell
251,237
-144,893
-37% -$15.2M 0.02% 315
2021
Q3 		$40.7M Sell
396,130
-8,371
-2% -$780K 0.03% 247
2021
Q2 		$35.6M Sell
404,501
-8,412
-2% -$771K 0.02% 277
2021
Q1 		$40.1M Buy
412,913
+391,572
+1,835% +$39.1M 0.03% 247
2020
Q4 		$2.39M Buy
+21,341
New +$2.25M ﹤0.01% 496
2020
Q2 		– Sell
-61,058
Closed -$3.57M – 635
2020
Q1 		$3.57M Buy
61,058
+416
+0.7% +$26.8K ﹤0.01% 422
2019
Q4 		$4.86M Sell
60,642
-47,408
-44% -$3.55M ﹤0.01% 435
2019
Q3 		$7.94M Sell
108,050
-79,635
-42% -$6.88M 0.01% 428
2019
Q2 		$17.7M Sell
187,685
-373
-0.2% -$30.8K 0.02% 370
2019
Q1 		$15.1M Buy
188,058
+209
+0.1% +$15.4K 0.01% 397
2018
Q4 		$10.1M Sell
187,849
-34,691
-16% -$2.11M 0.01% 433
2018
Q3 		$17.4M Buy
222,540
+1,658
+0.8% +$115K 0.02% 416
2018
Q2 		$14M Buy
220,882
+12,408
+6% +$987K 0.01% 441
2018
Q1 		$19.1M Buy
208,474
+28,389
+16% +$2.45M 0.02% 397
2017
Q4 		$13.6M Sell
180,085
-48,532
-21% -$3.41M 0.01% 443
2017
Q3 		$15.9M Sell
228,617
-525
-0.2% -$28.1K 0.02% 434
2017
Q2 		$11.6M Buy
229,142
+79,142
+53% +$3.36M 0.01% 463
2017
Q1 		$6M Buy
+150,000
New +$5.37M 0.01% 503

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates's BPMC Position: Q2 2025 in Review

Jennison Associates sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 348,817 shares — an estimated $30.9M sold.

Jennison Associates first reported a position in BPMC in Q1 2017 and held it in 20 quarters. The position peaked at $40.7M in Q3 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Jennison Associates reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Jennison Associates sold 348,817 Blueprint Medicines shares in Q2 2025, an estimated $30.9M.
  • Jennison Associates first reported a position in Blueprint Medicines in Q1 2017 and held it in 20 quarters.
  • Jennison Associates's Blueprint Medicines position peaked at $40.7M in Q3 2021.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Jennison Associates's 13F filing for Q2 2025, filed 1 Aug 2025.